Intelligence / Healthtech / New Clinical Trials
ClinicalLIVEUpdated 18 Nov 2026
New Clinical Trials
Clinical trials companies registered in the last 30 days, worldwide, with the sponsor, phase and countries.
Sources: ClinicalTrials.gov · Rebuilt weekly · Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase.
Trials
777
in the 30 days to 2026-11-18
Added in 30 days
777
to 18 Nov 2026
Top country
United States
192 · 25% of the list
Phase covered
8
distinct values
Snapshot · 18 Nov 2026
Explore all 777 Growth
By month
777
Signals
What the register says this week, and why it matters if you sell into it.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
- 174 of the listed studies are device, diagnostic or digital-health studies (no drug phase).
- A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
PostedSponsorStudyPhaseStatus
10 Nov 2026Xiamen Amoytop Biotech Co., Ltd.ChinaACT201 Injection in Participants With Chronic Hepatitis B (CHB) on Nucleos(t)Ide Analog Therapy - Phase IbPhase 1Not Yet Recruiting9 Nov 2026AbbVieUnited StatesA Study to Assess How Intravenous and Subcutaneous Administrations of Trosunilimab Move Through the Body of Healthy Adult ParticipantsPhase 1Recruiting9 Nov 2026Amazentis SABioavailability of Two Mitopure FormulationsNot applicableNot Yet Recruiting9 Nov 2026Amway (China) R&D CenterChinaExplore the Weight Loss Effect of Amway "BODY TRIMMER"Not applicableRecruiting9 Nov 2026Aqua Therapeutics, Inc.Austria, ItalyClinical Study on the Safety and the Performance of an Endometrial Ablation System in Women With Abnormal Uterine Bleeding (AUB) and Previous Cesarean DeliveryNot applicableRecruiting9 Nov 2026Ascendis Pharma A/SClinical Trial Evaluating the Efficacy and Safety of Navepegritide and Lonapegsomatropin in AchondroplasiaPhase 3Not Yet Recruiting9 Nov 2026Beijing InnoCare Pharma Tech Co., Ltd.ChinaA Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) PatientsPhase 3Recruiting9 Nov 2026Boehringer IngelheimJapanReal-world Outcome of Zongertinib in Japan (J-HERZ)Not Yet Recruiting9 Nov 2026Boehringer IngelheimUnited States, Belgium, FinlandA Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard TreatmentPhase 2Not Yet Recruiting9 Nov 2026Boehringer IngelheimUnited States, Australia, JapanA Study of BI 4015092, Alone or in Combination With Other Cancer Treatment, in Patients With Advanced Cancer That Has a KRAS G12D MutationPhase 1Not Yet Recruiting9 Nov 2026Boston Scientific CorporationCroatia, Czechia, FranceThe Evaluation of User Experience With FARAVIEW™ Technology of the OPAL HDx™ Mapping System When Used With the FARAWAVE NAV™ ULTRA Pulsed Field Ablation Catheter in the Treatment of Atrial FibrillationNot applicableNot Yet Recruiting9 Nov 2026CB ConsultingUnited StatesRetrospective Evaluation of Visual Outcomes, Safety and Enhancement Rates Following Wavefront-Guided LASIK Using a 10 MHz Elita Femtosecond LaserRecruiting9 Nov 2026Clement Therapeutics, Inc.CMT-133 in Healthy Adult ParticipantsPhase 1Not Yet Recruiting9 Nov 2026CSPC Megalith Biopharmaceutical Co.,Ltd.ChinaA Study of SYS6010 Combined With Enlonstobart in Patients With Previously Systemic Treatment-Naive R/M Nasopharyngeal CarcinomaPhase 3Recruiting9 Nov 2026CSPC Megalith Biopharmaceutical Co.,Ltd.Immunogenicity and Safety of SYS6057 in the Participants Aged 18 Years and AbovePhase 1Not Yet Recruiting9 Nov 2026CSPC Megalith Biopharmaceutical Co.,Ltd.A Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Enlonstobart, With or Without SYS6010 as Adjuvant Therapy, in Participants With Pathologically Residual Esophageal Squamous Cell Carcinoma Following Complete Surgical ResectionPhase 3Not Yet Recruiting9 Nov 2026EktaHTunisiaA Single Ascending Dose and Multiple Ascending Dose Trial to Assess the Dose, the Efficacy and Oro-sensitivity of Two Modified Linoleic Acids NKS-3 and NKS-5Phase 1Completed9 Nov 2026Femasys Inc.SpainA Study to Evaluate the Acceptability of the FemBloc System as a Non-surgical, Permanent Contraceptive MethodActive Not Recruiting9 Nov 2026FixNip LtdUnited StatesPREFIX FEASIBILITY Study - PRojection & Safety Evaluation of the FIXNip Nipple Reconstruction ImplantNot applicableRecruiting9 Nov 2026FUSMobile Inc.SpainStudy Designed to Assess the Efficacy and Safety of the Neurolyser XR After Marketing ApprovalNot Yet Recruiting9 Nov 2026HK inno.N CorporationSouth KoreaObservational Study to Evaluate Achieving LDL-cholesterol Target Level to Treat With Rovazet Tab. With Dyslipidemia PatientsRecruiting9 Nov 2026Iongen Therapeutics Co., Ltd.New ZealandA Study to Assess IG001643 in Healthy ParticipantsPhase 1Not Yet Recruiting9 Nov 2026KaileraUnited StatesA Study to Investigate the Effect of Injection Site and Ethnicity on KAI-4729 Pharmacokinetics in Non-Asian and Asian Participants Living With Obesity or OverweightPhase 1Not Yet Recruiting9 Nov 2026Mighty Therapeutics Inc.A Clinical Trial to Evaluate the Efficacy and Safety of Bevemipretide Ophthalmic Topical Solution in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD)Phase 2, Phase 3Not Yet Recruiting9 Nov 2026Molnlycke Health Care ABItalyInterventional Study to Describe the Utilization of Foam Dressings in Routine Clinical Practice, for the Treatment of Patients With Chronic Wounds in a Primary Healthcare Center in Italy.Not applicableRecruiting9 Nov 2026Perfect Care DistributionRomaniaHalova Vaginal Ovules Versus Placebo for Genitourinary Symptoms in Premenopausal WomenNot applicableCompleted9 Nov 2026PfizerUnited StatesA Study to Assess the Safety of Marstacimab and How Well it Works in People With Mild to Moderate Hemophilia A or B Without InhibitorsPhase 3Recruiting9 Nov 2026PfizerA Study to Learn About a Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple MyelomaNot Yet Recruiting9 Nov 2026Pharmosa Biopharm Inc.Efficacy and Safety Study of L608 in Patients With Systemic Sclerosis-associated Digital UlcersPhase 2Not Yet Recruiting9 Nov 2026Qilu Pharmaceutical Co., Ltd.A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerPhase 3Not Yet Recruiting9 Nov 2026Richmond Research InstituteUnited KingdomChronic Respiratory Disease Participant Engagement StudyRecruiting9 Nov 2026Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and CompanyUnited StatesA Study of Tersolisib (LY4064809) in Participants With Kidney Impairment Compared With Participants With Normal Kidney FunctionPhase 1Not Yet Recruiting9 Nov 2026Triastek, lnc.ChinaA Pharmacokinetic Study of Budesonide Delayed Release Tablet D23A (D23) in Healthy Chinese Participants Under Fasting ConditionsPhase 1Active Not Recruiting9 Nov 2026XeltisPost Market Clinical Follow-Up Registry Study of the aXess Hemodialysis ConduitNot applicableNot Yet Recruiting6 Nov 2026AmgenComparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations After Multiple DosesPhase 1Not Yet Recruiting6 Nov 2026AstraZenecaChina, IndiaA Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 DiabetesPhase 3Not Yet Recruiting6 Nov 2026Beijing Pins Medical Co., LtdChinaClinical Trial of SEEG for Drug-resistant EpilepsyNot applicableNot Yet Recruiting6 Nov 2026BELL Therapeutics Inc.South KoreaSmartphone Camera Measurement of Breathing-Related Heart Rate Variability Compared With ECG in Healthy AdultsNot applicableNot Yet Recruiting6 Nov 2026Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd.ChinaA Phase I Dose Escalation Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid TumorsPhase 1Recruiting6 Nov 2026Chengdu SciMount Pharmatech Co., Ltd.ChinaA First-in-human Study of SMP-656 in Subjects With Locally Advanced/ Metastatic HER2 Expressing or Mutated Solid TumorsPhase 1Completed6 Nov 2026Dartsbio Pharmaceuticals Ltd.AustraliaPhase 1/2 Study of DS010 in Advanced Cancer Patients With CachexiaPhase 1, Phase 2Recruiting6 Nov 2026Eli Lilly and CompanyUnited States, Hungary, ItalyA Study of Bimagrumab in Participants With HFpEFPhase 2Not Yet Recruiting6 Nov 2026Epirium Bio Inc.MF-300 for Treatment of Age-Related SarcopeniaPhase 2Not Yet Recruiting6 Nov 2026Gan & Lee Pharmaceuticals.ChinaA Phase I Study of GLR2053 Tablets in Chinese Healthy Adult ParticipantsPhase 1Not Yet Recruiting6 Nov 2026Guangdong Hengrui Pharmaceutical Co., LtdChinaA Trial Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Palmoplantar PustulosisPhase 2Not Yet Recruiting6 Nov 2026Haisco Pharmaceutical Group Co., Ltd.A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic DermatitisPhase 1Not Yet Recruiting6 Nov 2026Hexin (Suzhou) Pharmaceutical Technology Co., LtdChinaEvaluation of the I-phase Clinical Trial of 177Lu-HX02 Injection in Patients With Advanced Malignant Solid TumorsPhase 1Enrolling By Invitation6 Nov 2026Hexin (Suzhou) Pharmaceutical Technology Co., LtdChinaA Multicenter Phase II Clinical Trial Evaluating 68Ga-HX01 Injection for PET/CT ImagingPhase 2Recruiting6 Nov 2026HK inno.N CorporationSouth KoreaEfficacy and Safety of K-CAB(Tegoprazan) 25 mg as Maintenance Therapy Following the Treatment of GERDRecruiting6 Nov 2026Huabo Biopharm Co., Ltd.ChinaA Study of HB0017 Injection in Healthy Volunteers to Evaluate Safety and Tolerability of a Single Subcutaneous Injection in Low-Body-Weight Subjects; and Pharmacokinetics at Different Subcutaneous Injection Sites at the Same DosePhase 1Recruiting// How AOS uses this